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Application of 𝛼-gal nanoparticles to wounds and burns induces accelerated healing by harnessing the natural anti-Gal
antibody which constitutes ∼1% of human immunoglobulins. 𝛼-gal nanoparticles present multiple 𝛼-gal epitopes (Gal𝛼1-3Gal𝛽1-
4GlcNAc-R), the carbohydrate ligand of anti-Gal. Studied 𝛼-gal nanoparticles were comprised of glycolipids with 𝛼-gal epitopes,
phospholipids, and cholesterol. Binding of anti-Gal to 𝛼-gal nanoparticles in wounds activates the complement cascade, resulting in
formation of chemotactic complement cleavage peptides that induce rapid recruitment ofmanymacrophages.The Fc/Fc𝛾 receptors
interaction between anti-Gal coating 𝛼-gal nanoparticles and the recruited macrophages activates macrophages to produce
cytokines/growth factors that promote wound healing and recruit stem cells. Studies of wound healing by 𝛼-gal nanoparticles
were feasible in 𝛼1,3galactosyltransferase knockout mice and pigs. In contrast to other nonprimate mammals, these mice and pigs
lack the 𝛼-gal epitope, and thus they are not immunotolerant to it and produce anti-Gal. Treatment of skin wounds and burns
with 𝛼-gal nanoparticles resulted in 40–60% decrease in healing time in comparison with control wounds treated with saline. This
accelerated healing is associated with increased recruitment of macrophages and extensive angiogenesis in wounds, faster regrowth
of epidermis, and regeneration of the dermis. The accelerated healing further decreases and may completely eliminate fibrosis and
scar formation in wounds. Since healing of internal injuries is mediated by mechanisms similar to those in external wound healing,
it is suggested that 𝛼-gal nanoparticles treatment may also improve regeneration and restoration of biological function following
internal injuries such as surgical incisions, myocardial ischemia following infarction, and nerve injuries.
1. Significance of Macrophages
in Wound Healing
Wounds that penetrate deep in the skin remain a major clin-
ical problem because of morbidity associated with prolonged
periods required for repair and regeneration of the injured
tissue, bleeding, risk for infections and septicemias, keloids,
and scar formation.These risk factors are further exacerbated
in patients with impaired wound healing as in diabetes and
in old age. Accelerating wound healing process can minimize
these risk factors. Moreover, because of the increase in the
proportion of aging individuals in the population in the
coming decade, the costs of clinical care for wound healing
are likely to greatly increase [1].
Healing of acute wounds requires the local effective
recruitment and activation of macrophages which are the
pivotal cells in early stages of injury healing. After debriding
the injured tissue by phagocytosis, macrophages undergo
transition into “prohealing” cells that mediate repair and
regeneration by secreting cytokines/growth factors that
induce regeneration of epidermis, dermis, and capillary
network (angiogenesis) [2–9]. Macrophages originate from
blood monocytes that migrate into the wound in response
to monocytes chemoattractant cytokines such as MCP-1
(monocyte chemoattractant protein-1), MIP-1 (macrophages
inflammatory protein 1), and RANTES (regulated on acti-
vation, normal T cell expressed and secreted) released from
cells within and around injury sites [10–15]. Whereas small
wounds may be completely healed and the injured tissue
regenerated within several days, the healing process of the
large wounds or burns may be much longer. A prolonged
healing increases the risk of infection and increases the
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probability of scar formation and prevention of remodeling
of the injured tissue into its original structure. Scar formation
is the default mechanism for repair of injuries. In scar
formation, a dense connective tissue (fibrosis) replaces the
original structure of the injured tissue.The longer the healing
time of a wound, the higher the probability that a scar will
be formed. Based on these considerations, it is reasonable to
assume that rapid recruitment of macrophages into wounds
may decrease morbidity, including the risk of infection, and
reduce the extent of scar formation, or completely avoid this
default repair mechanism.
A very effective physiologic mechanism for inducing
rapid recruitment of macrophages into wounds is the acti-
vation of the complement system within injured tissues
by antigen/antibody (Ag/Ab) interaction. Such activation
results in generation of chemotactic complement cleavage
peptides, including C5a and C3a which induce vasodila-
tion, extravasation of blood monocytes, maturation of these
monocytes into macrophages, and their migration along
the complement chemotactic gradient into the complement
activation site. This mechanism is of major significance in
microbial infections where Ab binding to microbial Ags
activates the complement system and generates chemotactic
complement cleavage peptides that induce rapid recruitment
of neutrophils and macrophages into the infection site [16–
18]. Rapid recruitment of macrophages into various injuries
is feasible by harnessing the immunologic potential of the
natural anti-Gal Ab [19–21]. This Ab is present in high
titers in all humans that are not severely immunocom-
promised [22]. Interaction of anti-Gal with 𝛼-gal nanopar-
ticles [23] within injuries results in effective activation
of the complement system, recruitment of macrophages,
and activation of the recruited macrophages to produce
“prohealing” cytokines/growth factors that decrease healing
time of injuries by 40–60% [19–21]. The accelerated wound
healing process further decreases or completely prevents scar
formation [19]. This review describes the natural anti-Gal
Ab, 𝛼-gal nanoparticles, and experimental models in which
anti-Gal/𝛼-gal nanoparticles interaction accelerates wound
healing. The review further discusses the possible use of 𝛼-
gal nanoparticles in treatment of various internal injuries.
2. The Natural Anti-Gal Ab and Its Ligand,
the 𝛼-gal Epitope
Anti-Gal is a natural Ab produced in humans throughout
life as ∼1% of circulating immunoglobulins [22] and is found
in the blood as IgG, IgM, and IgA classes [22, 24–27]. This
Ab displays characteristics similar to anti-blood group A
and anti-blood group B natural Abs in that its ligand is
also a carbohydrate Ag called the 𝛼-gal epitope, with the
structure Gal𝛼1-3Gal𝛽1-4GlcNAc-R [28]. In addition, like
these anti-blood group Abs, anti-Gal is produced in response
to continuous antigenic stimulation by bacteria of the normal
gastrointestinal flora that present carbohydrate Ags with
structures similar to the 𝛼-gal epitope [29]. However, in con-
trast to anti-A and anti-B Abs which are produced according
to the blood type of each individual, anti-Gal is naturally
produced in all humans. As many as 1% of circulating B
cells in humans is capable of producing anti-Gal following
immortalization by Epstein Barr virus (EBV), only ∼0.2% of
EBV immortalized B cells produces anti-A or anti-B Abs [30].
The majority of anti-Gal B cells in the body are quiescent,
whereas those along the gastrointestinal track produce anti-
Gal following antigenic stimulation by gastrointestinal bacte-
ria. Complementmediated lysis following anti-Gal binding to
𝛼-gal epitopes has been observed with various nucleated cells
[31–33] and with enveloped viruses presenting this epitope
[34–36].
Anti-Gal and the 𝛼-gal epitope display a unique distribu-
tion inmammals. All nonprimatemammals tested (e.g.,mice,
rats, rabbits, dogs, pigs, etc.) as well as prosimians (lemurs)
and New World monkeys (monkeys of South America) lack
the anti-Gal Ab, but all produce its ligand the 𝛼-gal epitope
as ∼105–107 epitopes/cell [37, 38]. In contrast, Old World
monkeys (monkeys of Asia and Africa), apes and humans
lack the 𝛼-gal epitope because they lack the glycosylation
enzyme 𝛼1,3galactosyltransferase (𝛼1,3GT) synthesizing this
epitope, but they all produce the natural anti-Gal Ab [22,
27, 37, 38]. Because of this reciprocal distribution of anti-
Gal and the 𝛼-gal epitope in mammals, xenotransplantation
of pig organs in humans or in Old World monkeys results
in rapid (hyperacute) rejection of the xenograft [39–42]. The
binding of anti-Gal of the xenograft recipient to the multiple
𝛼-gal epitopes on the xenograft endothelial cells induces
complement activation and complement mediated cytolysis
of these cells, resulting in rapid collapse of the vascular bed
and rejection of the graft [40–42].This complementmediated
hyperacute rejection of xenografts is an in vivo manifestation
of the effective complement activation by the natural anti-Gal
Ab.
In addition to induction of complement mediated cytol-
ysis, anti-Gal interaction with glycoproteins, viruses, or cells
presenting 𝛼-gal epitopes opsonizes them and induces their
effective uptake by various cells with Fc𝛾 receptors (Fc𝛾R)
including macrophages, dendritic cells, and NK cells [39, 43,
44]. It is further probable that deposits of the complement
molecule C3b on cells or on particles binding anti-Gal
also mediate uptake of various anti-Gal opsonized cells or
particles into macrophages by interaction with C3b receptors
(C3bR, also referred to as CR1 and CD35) on these cells.
The ubiquitous presence of anti-Gal in large amounts
in all humans who are not severely immunocompromised
provides an opportunity for harnessing this Ab for various
therapies. In previous studies in 𝛼1,3GT knockout mice,
anti-Gal was shown to enable the induction of a protective
antitumor immune response by in vivo targeting tumor cells
engineered to present 𝛼-gal epitopes to antigen presenting
cells (APC) [45–47]. Similarly, viral vaccines presenting 𝛼-
gal epitopes and immunocomplexed in vivo with anti-Gal
were effectively targeted to APC and thus increased their
immunogenicity by 10–100-fold [48, 49]. As described below,
anti-Gal mediated complement activation and opsonization
for Fc𝛾Rmediated uptake by macrophages further accelerate
wound healing following treatment of wounds with 𝛼-gal
nanoparticles.
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Figure 1: Illustration of 𝛼-gal nanoparticle and the process of accelerated wound healing induced by these nanoparticles. The studied 𝛼-gal
nanoparticles are comprised of phospholipids, cholesterol, and 𝛼-gal glycolipids that carry 𝛼-gal epitopes (a representative 10 carbohydrate
glycolipid with two branches, each capped with an 𝛼-gal epitope, marked by a dashed line rectangle). Application of 𝛼-gal nanoparticles to
injuries results in the induction of the following sequential steps. (1) The natural anti-Gal Ab binds to 𝛼-gal epitopes on the nanoparticles
and activates the complement system, resulting in formation of complement cleavage chemotactic peptides. (2)The chemotactic complement
peptides induce rapid and extensive recruitment of macrophages into the treated injury. (3) The 𝛼-gal nanoparticles activate the recruited
macrophages as a result of interaction between the Fc portion of anti-Gal coating the nanoparticles and Fc𝛾 receptors (Fc𝛾R) onmacrophages.
(4) The activated macrophages produce “prohealing” cytokines/growth factors. (5) Secreted cytokines/growth factors further mediate rapid
recruitment of stem cells into the injury site. Modified from [21].
3. 𝛼-gal Nanoparticles Interaction with
the Anti-Gal Ab
𝛼-gal nanoparticles are submicroscopic particles presenting
multiple 𝛼-gal epitopes. Such nanoparticles may be prepared
from various biodegradable materials. In studies on the effect
of 𝛼-gal nanoparticles on wound healing, the nanoparticles
with size range of 30–300 nmwere prepared from glycolipids
with multiple 𝛼-gal epitopes (𝛼-gal glycolipids), phospho-
lipids, and cholesterol (Figure 1) [19, 21].Thesematerials were
obtained from chloroform: methanol extracts of rabbit RBC
membranes.These RBC are suitable for the purpose of prepa-
ration of 𝛼-gal nanoparticles since they present the highest
concentration of 𝛼-gal epitopes amongmammalian RBC and
since most of the glycolipids in their membranes carry 𝛼-
gal epitopes [37, 47, 50–55]. Rabbit RBC membranes are
incubated in chloroform: methanol solution. Residual RBC
membranes and proteins precipitates are removed by filtra-
tion.The extract comprised of glycolipids, phospholipids, and
cholesterol is dried then sonicated in saline in a sonication
bath to generate ∼4.0 gm 𝛼-gal liposomes from 1.0 liter rabbit
RBC (∼1015 𝛼-gal epitopes/mg). These liposomes are further
sonicated by a sonication probe on ice, into submicroscopic
𝛼-gal nanoparticles which are filtered through 0.45 𝜇m filter
and then through 0.2 𝜇m filter to ensure sterility [19, 21, 23].
The nanoparticles produced by this method have a wall of
phospholipids and cholesterol in which 𝛼-gal glycolipids are
anchored via the fatty acid tails of their ceramide portion
(Figure 1). The illustrated glycolipid in Figure 1 has 10 sugar
units in its carbohydrate chain and 2 branches (antennae),
each capped with an 𝛼-gal epitope. The 𝛼-gal glycolipids
originating from rabbit RBC membranes and presented on
these 𝛼-gal nanoparticles are of various lengths ranging from
5 to 40 carbohydrate units and carrying 1–8 branches each
capped with an 𝛼-gal epitope [50–55]. The 𝛼-nanoparticles
are highly stable since they contain no tertiary structures
and can be kept at 4∘C or −20∘C for several years without
losing activity. This stability is indicated by the similarity in
the ability of 𝛼-gal nanoparticles kept at 4∘C for 4 years and
that of freshly prepared 𝛼-gal nanoparticles to bind anti-Gal,
as measured by ELISA (using 𝛼-gal nanoparticles as solid-
phase Ag), and by the ability of the two 𝛼-gal nanoparticles
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preparations to activate serum complement following anti-
Gal binding, as assayed in complement consumption assays
(unpublished observations).
Based on the extensive in vitro interaction between anti-
Gal and 𝛼-gal nanoparticles, it could be expected that, follow-
ing topical application of these nanoparticles to wounds, they
will readily bind the natural anti-Gal Ab that is released from
ruptured blood vessels within the wound and is present in the
fluid film in wounds. As schematically illustrated in Figure 1,
this Ag/Ab interaction activates the complement system,
generating chemotactic peptides that recruit macrophages
which bind the anti-Gal coated nanoparticles and produce
cytokines and growth factors that orchestrate the healing
of wounds [19–21, 23]. The experiments demonstrating the
various processes involved in 𝛼-gal nanoparticles mediated
wound healing are described in sections below.
4. Experimental Animal Models for Studying
Anti-Gal/𝛼-gal Nanoparticles Interaction
In vivo studies on anti-Gal mediated effects of 𝛼-gal nanopar-
ticles cannot be performed in standard experimental ani-
mal models since mice, rats, guinea-pigs, rabbits, and pigs
(as well as other nonprimate mammals) all produce 𝛼-
gal epitopes on their cells by the glycosylation enzyme
𝛼1,3galactosyltransferase (𝛼1,3GT) [37, 38]. Therefore, non-
primate mammals cannot produce anti-Gal as they are
immunotolerant to the𝛼-gal epitope [37, 38, 56]. As indicated
above, Old World monkeys, apes and humans are the only
mammalian species producing anti-Gal since they lack the 𝛼-
gal epitope [22, 27, 37]. However, in the recent two decades,
several groups succeeded in generating 𝛼1,3GT knockout
mice (GT-KOmice) [57, 58] and 𝛼1,3GT knockout pigs (GT-
KO pigs) [59–61]. These knockout mice and pigs lack 𝛼-gal
epitopes because of targeted disruption (knockout) of the
𝛼1,3GT gene, and thus they are not immunotolerant to it
[19, 58, 62, 63]. Because GT-KO mice are usually kept in a
clean environment they lack the gastrointestinal flora that
induces production of the natural anti-Gal Ab and therefore,
natural production of this Ab is usually low. However, these
mice readily produce anti-Gal following few immunizations
with xenograft tissues expressing multiple 𝛼-gal epitopes,
such as pig kidney membrane homogenate [19]. In contrast,
GT-KO pigs have the required natural flora and thus produce
the natural anti-Gal Ab [62, 63]. Both GT-KO mice and GT-
KO pigs were found to be suitable experimental models for
studying the effects of 𝛼-gal nanoparticles on wound healing
[19–21].
5. Recruitment of Macrophages by
𝛼-gal Nanoparticles
As indicated in Figure 1, it is expected that the first event
which occurs following application of 𝛼-gal nanoparticles to
wounds is the interaction between serum anti-Gal and 𝛼-
gal epitopes on these nanoparticles. This interaction leads
to activation of the complement system (Step 1 in Figure 1).
The in vivo activation of complement following anti-Gal/𝛼-
gal epitope interaction has been repeatedly demonstrated in
xenotransplantation studies in which xenografts expressing
𝛼-gal epitopes on their endothelial cells underwent com-
plement mediated hyperacute rejection following binding of
the recipient’s anti-Gal to xenograft 𝛼-gal epitopes [40–42].
Accordingly, no such hyperacute rejection has been observed
when the xenograft was obtained from a GT-KO pig lacking
𝛼-gal epitopes [64–66]. Like anyAg/Ab interaction activating
the complement cascade, also complement activation by anti-
Gal binding to 𝛼-gal nanoparticles results in production of
complement cleavage peptides including C5a and C3a. These
complement cleavage peptides are among the most potent
physiologic chemotactic factors (chemoattractants) which
induce rapid recruitment of macrophages (Step 2 in Figure 1).
Recruitment of macrophages could be demonstrated
following intradermal injection of 10mg 𝛼-gal nanoparticles
in anti-Gal producing GT-KO mice. Extensive macrophage
recruitment at the injection sites was observed already
within 24 h after injection of the nanoparticles (Figure 2(a)).
It should be noted that recruitment of neutrophils was
observed within 12 h after injection [19]. However, after 24 h,
most of the neutrophils disappeared and the recruited cells
were primarily macrophages. By 48 h no neutrophils were
found at the injection site, whereas the number of recruited
macrophages further increased [19]. Immunostaining of the
recruited cells on day 4 by the macrophage specific anti-
F4/80 Ab indicated that most of these cells were indeed
macrophages (Figure 2(b)). By day 7, the recruited cells
were large and displayed ample cytoplasm, suggesting acti-
vation of the macrophages (Figure 2(c)). Individual isolated
macrophages were found to be very large (20–30𝜇m) and
containedmultiple vacuoles that represented the internalized
𝛼-gal nanoparticles (Figure 2(d)). The presence of multiple
macrophages at the injection site was also observed on day
14 after injection [19]. However, by day 21 all macrophages
disappeared and the skin displayed complete restoration of
its normal structure with no indication of granuloma. This
finding raises the possibility that all macrophages migrate
away from the 𝛼-gal nanoparticles injection site after 3 weeks.
Intradermal injection of 𝛼-gal nanoparticles in wild-type
(WT) mice (i.e., mice producing 𝛼-gal epitopes and lacking
anti-Gal) did not induce recruitment of macrophages [19].
This implied that the observed recruitment of macrophages
in GT-KO mice was dependent on the presence of anti-Gal
which interacts with 𝛼-gal nanoparticles (Step 1 in Figure 1).
The need for complement activation for recruitment of
macrophages was further demonstrated by inhibition of the
complement activation process. Intradermal injection of 𝛼-
gal nanoparticles together with cobra venom factor (inhibitor
of complement activation cascade) into GT-KOmice resulted
in no recruitment of macrophages [19]. This finding strongly
suggests that macrophage recruitment (Step 2 in Figure 1)
is dependent on complement cleavage chemotactic factors
formed as a result of complement activation by anti-Gal/𝛼-
gal nanoparticles interaction.
The recruited macrophages in GT-KO mice were further
studied in biologically inert polyvinyl alcohol (PVA) sponge
discs containing 10mg 𝛼-gal liposomes (𝛼-gal nanoparticles
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Figure 2: Recruitment of macrophages by 10mg 𝛼-gal nanoparticles injected intradermal in anti-Gal producing GT-KO mice. (a)
Macrophages migrating toward the injection site, 24 h after injection. The injection site is indicated as the empty area since the 𝛼-gal
nanoparticles are dissolved by the alcohol fixative (H&E ×100). (b) The injection site after 4 days immunostained with macrophage specific
HRP-anti-F4/80Ab.The recruited cells are stained by this Ab (×200). (c)The injection site after 7 days demonstratingmany largemacrophages
with ample cytoplasm (H&E ×400). (d) Individual macrophages isolated on day 7 displaying large size and multiple cytoplasmic vacuoles,
probably the result of activation and uptake of the anti-Gal coated 𝛼-gal nanoparticles (Wright staining ×1000). Modified from [19].
with size >1 𝜇m) and implanted subcutaneously. All recruited
cells retrieved from these implanted PVA sponge discs 3, 6,
or 9 days after implantation were stained with macrophage
specific anti-CD11b and anti-CD14 Abs [20]. No recruited T
cells or B cells were detected in the PVA sponge discs. The
cells retrieved from the sponge discs on day 6 displayed the
morphology of large macrophages with multiple cytoplasmic
vacuoles that may represent internalized anti-Gal coated 𝛼-
gal liposomes [20]. In absence of 𝛼-gal nanoparticles in
implanted PVA sponge discs, recruitment of macrophages
was ∼90% lower than in presence of these nanoparticles [20].
6. Activation of the Recruited Macrophages
by Fc/Fc𝛾R Interaction
Step 3 in Figure 1 illustrates activation of the recruited
macrophages reaching the 𝛼-gal nanoparticles as a result of
interaction between the Fc “tails” of anti-Gal coating 𝛼-gal
nanoparticles and Fc𝛾R on these macrophages. This Fc/Fc𝛾R
interaction between anti-Gal coated 𝛼-gal nanoparticles and
macrophages is demonstrated in Figure 3 where the nanopar-
ticles coated with anti-Gal were incubated with GT-KO pig
macrophages for 2 h. This coincubation resulted in attach-
ment of multiple 𝛼-gal nanoparticles to the macrophages
via the Fc/Fc𝛾R interaction. No significant binding of
𝛼-gal nanoparticles to macrophages was observed if the
nanoparticles were not coated with anti-Gal [23]. A similar
Fc/Fc𝛾R interaction was observed with 𝛼-gal nanoparticles
coated with GT-KO mouse anti-Gal, incubated with mouse
macrophages and analyzed for binding by flow cytometry
[19].
The binding of 𝛼-gal nanoparticles to macrophages via
Fc/Fc𝛾R interaction seemed to activate themacrophages.This
is suggested by the large size of the macrophages observed
subcutaneously 7 days after administration of the nanopar-
ticles (Figures 2(c) and 2(d)). Activation of macrophages
binding the 𝛼-gal nanoparticles is further indicated by the
production of various “prohealing” cytokines/growth factors
capable of accelerating wound healing, as hypothesized in
Step 4 of Figure 1. VEGF is one of the pivotal cytokines
in wound healing which induces vascularization of the
healing wound. In vitro incubation for 24 h of GT-KO
mousemacrophages with anti-Gal coated𝛼-gal nanoparticles
resulted in production of VEGF at a level that was twice as
high as that secreted by macrophages in the absence of 𝛼-
gal nanoparticles [19]. Incubation of macrophages with 𝛼-gal
nanoparticles in the absence of anti-Gal resulted in VEGF
production at a level similar to the control level produced by
macrophages incubated without the nanoparticles [19].
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Figure 3: Scanning electron microscopy of anti-Gal coated 𝛼-gal nanoparticles binding to macrophages via Fc/Fc𝛾R interaction. 𝛼-gal
nanoparticles coated with anti-Gal Ab were coincubated with adherent GT-KO pig macrophages for 2 hours at room temperature, washed
to remove nonadherent nanoparticles, and processed for electron microscopy analysis. Many 𝛼-gal nanoparticles adhere to the surface of a
representative macrophage. The inset in (a) is enlarged in (b). Modified from [23].
The increased production of VEGF by activated mac-
rophages within wounds is further suggested by the extensive
vascularization of wounds in GT-KO pigs treated with 𝛼-gal
nanoparticles (Figure 4). As further detailed in the section
on GT-KO pig wound healing below, wounds on the back of
those pigs were 20 × 20mm and ∼3mm deep. The wounds
were treated by topical application of 𝛼-gal nanoparticles
or saline and covered with dressing which was replaced
every 3-4 days [21]. As expected, the day 13 granulation
tissue in wounds treated with 𝛼-gal nanoparticles contained
many more macrophages than that in saline treated wounds
(Figure 4). In addition, the day 13 granulation tissue in the
𝛼-gal nanoparticles treated wounds (Figures 4(a) and 4(c))
displayed a much higher concentration of blood vessels than
that in saline treated wounds of the sameGT-KO pig (Figures
4(b) and 4(d)). This higher vascularization may reflect the
increased production of VEGF in 𝛼-gal nanoparticles treated
wounds because of activation of recruited macrophages by
anti-Gal coated 𝛼-gal nanoparticles that interact with Fc𝛾R
of the macrophages (Step 4 in Figure 1).
An alternative approach formeasuring in vivo production
of various cytokines/growth factors was quantitative real
time (RT) PCR for mRNA level of such cytokines within
skin of GT-KO mice injected with 𝛼-gal nanoparticles.
Such analysis demonstrated increased production of FGF,
IL1, PDGF, and CSF in comparison to GT-KO mouse
skin injected with nanoparticles lacking 𝛼-gal epitopes [19].
These findings further support the assumption that recruited
macrophages undergoing Fc/Fc𝛾R interaction with anti-Gal
coated 𝛼-gal nanoparticles are activated to produce and
secrete cytokines/growth factors that promote repair and
regeneration of injured tissues. The recruitment of stem cells
by the cytokines/growth factors secreted from these activated
macrophages (Step 5 in Figure 1) was studied in PVA sponge
discs containing porcine meniscus cartilage extracellular
matrix (ECM) homogenate mixed with 𝛼-gal nanoparticles.
Such PVA sponge discs were implanted subcutaneously for
5 weeks in anti-Gal producing GT-KO mice [67]. Demon-
stration of meniscus like fibrocartilage generation in such
sponge discs suggested that stem cells recruited into these
PVA sponge discs by secretions from activated macrophages
were “instructed” by the meniscus cartilage ECM fragments
to differentiate into fibrochondroblasts that produce fibrocar-
tilage [67].
7. Treatment of Wounds with 𝛼-gal
Nanoparticles in GT-KO Mice
The effect of 𝛼-gal nanoparticles treatment on the healing
of skin wounds was first studied in anti-Gal producing GT-
KO mice. Oval-shaped excisional deep skin wounds with
the size of ∼3 × 6mm were formed under anesthesia in the
right abdominal flank of the mice. The wounds were covered
with spot bandage coated with 10mg 𝛼-gal nanoparticles or
with 10mg nanoparticles lacking 𝛼-gal epitopes (prepared
from GT-KO pig RBC). Control wounds were covered with
spot bandages containing saline. Wounds treated with 𝛼-gal
nanoparticles displayed 95–100% healing (i.e., most or all the
wound surface area was covered with regrown epidermis)
within 6 days after treatment [19]. In contrast, wounds
treated with nanoparticles lacking 𝛼-gal epitopes or those
treated with saline displayed only marginal regrowth of the
epidermis which covered <20% of the wound surface at day 6
after treatment [19]. The wounds treated with nanoparticles
lacking 𝛼-gal epitopes or with saline displayed 95–100%
healing only by days 12–14. These studies indicated that the
treatment of GT-KOmouse wounds with 𝛼-gal nanoparticles
decreased the healing time by >50% in comparison to control
wounds treated with saline or with nanoparticles lacking
𝛼-gal epitopes. Histological evaluation of wounds further
indicated that the processes of vascularization, fibroblast
migration, and collagen deposition in the dermis also are
accelerated in wounds treated with 𝛼-gal nanoparticles in
comparison to saline treated wounds [19]. Studies performed
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Figure 4: Vascularization of GT-KOpig wounds treated with 𝛼-gal nanoparticles (100mg) or with saline and studied on day 13.The presented
histology is of the centers of wound (not covered by regenerating epidermis), or wound areas under the leading edge of regenerating epidermis
treated with 𝛼-gal nanoparticles (a and c, resp.) or with saline (b and d, resp.). There are many more macrophages and blood vessels (filled
with red stained RBC) in wound treated with 𝛼-gal nanoparticles than in those treated with saline. Representative wounds from 6 GT-KO
pigs (H&E ×200). Modified from [21].
with 𝛼-gal liposomes (𝛼-gal nanoparticles with size >1 𝜇m)
were also found to induce acceleration of wound healing.
However, 𝛼-gal nanoparticles formed following extensive
sonication of 𝛼-gal liposomes were found to be somewhat
more effective in accelerating wound healing than compa-
rable amounts of liposomes. This improved healing of the
submicroscopic nanoparticles is possibly because of better
dispersion throughout the wound [19].
In studies with 𝛼-gal liposomes which preceded those
with 𝛼-gal nanoparticles, these liposomes were also found to
accelerate healing of burns in GT-KO mice. Small thermal
injuries (2 × 3mm) were performed in the shaved skin
of anesthetized anti-Gal producing GT-KO mice by a brief
touch of a heated metal spatula. Such burns are comparable
to second degree burns in humans in that the epidermis and
part of the dermis are damaged by the thermal injury. The
burns were covered with spot bandages coated with 10mg 𝛼-
gal liposomes, or with saline as control [20]. Burns treated
with 𝛼-gal liposomes displayed a much faster recruitment of
neutrophils and macrophages than those treated with saline.
Moreover, 𝛼-gal liposomes treated burns were covered with
regenerating epidermis, including Stratum corneum by day
6 after treatment, whereas saline treated wounds displayed
similar healing only after ∼12 days [20]. No acceleration of
burn healing was observed in wild-type mice (lacking anti-
Gal) treated with 𝛼-gal liposomes in comparison to burns
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Figure 5: Prevention of scar formation in GT-KOmouse wounds treated with 𝛼-gal nanoparticles. Representative wound treated for 28 days
with 𝛼-gal nanoparticles and stained with H&E (a) and with trichrome (c). Representative saline treated wound after 28 days, stained with
H&E (b) andwith trichrome (d). Collagen is stained blue by trichrome.𝛼-gal nanoparticles treatedwounds (a, c) display restoration of normal
skin structure, including thin epidermis, loose connective tissue in the dermis and appearance of skin appendages including hair, sebaceous
glands, fat andmuscle cells in the hypodermis. Saline treated wounds (b, d) undergo fibrosis to form a scar characterized by dense connective
tissue as a result of extensive collagen secretion by multiple infiltrating fibroblasts, no skin appendages and hyperplastic epidermis. The hair
shafts in the left are of the uninjured area bordering the wound. Scale bar in (d) is 100 𝜇m (×100). Specimens are representative of 5 mice per
group. Modified from [19].
treated with saline, further implying that the accelerated
healing process occurs only in the presence of the anti-Gal Ab
and thus, is dependent on anti-Gal/𝛼-gal epitopes interaction.
8. Prevention of Scar Formation Following
Treatment with 𝛼-gal Nanoparticles
Small wounds usually heal fast and restore the original
structure and cellular composition of the tissue. However,
injuries of large size are slow to heal because of the extensive
vascularization and the high number of cells required for
repopulation of the injured tissue. Under such circumstances
the default mechanism of fibrosis replaces the slower repair
and regeneration processes. This fibrosis consists of forma-
tion of dense connective tissue and low level of vasculariza-
tion, resulting in scar formation. The fibrotic scar serves as
barrier between pathogens in the external environment and
inner tissues. Thus, it was of interest to determine whether
wounds treated with 𝛼-gal nanoparticles display fibrosis and
scar formation similar to that observed in saline treated
wounds.
Wounds of GT-KOmice treatedwith saline and inspected
28 days after treatment displayed a large area of dense fibrotic
dermis devoid of skin appendages and a distinct epidermal
hyperplasia (≥5 layers of cells), both characteristic to scar
formation (Figures 5(b) and 5(d)) [19]. In contrast, 𝛼-gal
nanoparticle treated wounds inspected after 28 days dis-
played dermis with normal density of collagen and epidermis
of normal 2-cell layers thickness (Figures 5(a) and 5(b)).
Moreover, 𝛼-gal nanoparticles treated wounds displayed in
the dermis regenerating appendages such as hair follicles
and sebaceous glands, as well as fat cells and muscle cells.
No granuloma, macrophages, or keloids were observed in 𝛼-
gal nanoparticles treated wounds or in control saline treated
wounds at 28 days [19]. It is probable that this absence of scar
tissue in wounds treated with 𝛼-gal nanoparticles is the result
of the accelerated repair and regeneration process induced by
anti-Gal interaction with the nanoparticles.This acceleration
of the healing process is likely to result in restoration of
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Figure 6: Healing of excisional wounds in the skin of GT-KO
pigs treated with 𝛼-gal nanoparticles or with saline and viewed
on day 13. The original size of the wounds was 20 × 20mm and
3mm deep. The border of wounds was marked by tattooed dots
to determine contraction during healing. Control wounds treated
with saline display partial regeneration of the epidermis as a result
of physiologic healing. However, wounds treated with 100mg 𝛼-
gal nanoparticles are almost completely or completely covered with
regenerating epidermis. Wounds treated with 10mg 𝛼-gal nanopar-
ticles heal faster than saline treated wounds, however, somewhat
slower than wounds treated with 100mg 𝛼-gal nanoparticles in the
same pig.There are no significant differences of wound contractions
between saline treated and 𝛼-gal nanoparticles treated wounds.
Modified from [21].
normal cellular skin components in the wound prior to the
onset of the fibrosis process; thus scar formation is avoided.
9. Accelerating Wound Healing in GT-KO Pigs
As indicated above, there are only two nonprimate mam-
malian experimental models that lack the 𝛼-gal epitope and
produce the anti-Gal Ab, GT-KO mice, and GT-KO pigs.
Whereas anti-Gal production has to be induced in GT-KO
mice [19, 45], GT-KOpigs naturally produce anti-Gal [62, 63].
Thus, it was of interest to determine whether the acceleration
of wound healing observed in GT-KO mice can be validated
in the large animal model of GT-KO pig in which the skin
structure is very similar to that of human skin.
Eight excisional 20 × 20mm square wounds (∼3mm
deep) were formed on the back of 3-month-old GT-KO pigs.
Borders of the wounds were marked by tattooed dots prior
to wounding in order to evaluate wound contraction. The
wounds in each GT-KO pig were treated by topical appli-
cation of 100mg 𝛼-gal nanoparticles in 1.0mL (4 wounds),
10mg 𝛼-gal nanoparticles (2 wounds), or saline (2 wounds)
and covered with dressings that were changed every 3-
4 days [21]. On day 7, all wounds were filled with equal
amounts of granulation tissue; however, the concentration of
macrophages was found to be higher in 𝛼-gal nanoparticles
treated wounds than in saline treated wounds [21]. Wound
size was not significantly different on day 7 in wounds treated
with 𝛼-gal nanoparticles or saline. Distinct differences in
wound healing were observed on day 13 (Figure 6). Wounds
treated with 100mg 𝛼-gal nanoparticles were completely
or almost completely covered with regenerating epidermis,
whereas saline treated wounds displayed only partial heal-
ing. Complete regeneration of epidermis in saline treated
wounds was observed only 18–22 days after wounding. On
day 13, the area not covered by regenerating epidermis in
wounds treated with 100mg 𝛼-gal nanoparticles was 10-fold
smaller than that in saline treated wounds (Figure 6) [21].
Moreover, the extent of angiogenesis was much higher in
𝛼-gal nanoparticles treated wounds than in saline treated
wounds (Figures 4(a) and 4(c) versus Figures 4(b) and 4(d),
resp.). No significant differences were observed, however,
in wound contraction (marked by conversion of tattooed
dots into stretched lines) in 𝛼-gal nanoparticles and saline
treated wounds (Figure 6).There seemed to have been a dose
response in the healing effect of 𝛼-gal nanoparticles. Healing
of wounds treated with 10mg 𝛼-gal nanoparticles was slower
than that observed in wounds treated with 100mg 𝛼-gal
nanoparticles but faster than that in saline treated wounds
(Figure 6) [21]. Healed wounds inspected 60 days after injury
displayed no keloids formation under any of the treatments.
The 𝛼-gal nanoparticles treated wounds also displayed hair
growth [21]. No scar formation was observed in both 𝛼-gal
nanoparticles and saline treated wounds.
Overall, these observations on accelerated healing of
wounds treated with 𝛼-gal nanoparticles in GT-KO pigs and
GT-KO mice, growth of skin appendages, absence of scar
tissue in GT-KO mice, and absence of keloids in both pig
and mouse experimental models, all suggest that similar
treatment in humans may induce accelerated wound healing
without adverse effects.
10. Methods for Application of
𝛼-gal Nanoparticles
Because the 𝛼-gal nanoparticles require interaction with the
natural anti-Gal Ab for the induction of accelerated healing
of wound, they are likely to be effective in “wet” wounds or
burns. The fluid films in such wounds are formed by plasma
containing anti-Gal and complement proteins leaking from
injured capillaries. In contrast, dry wounds covered with a
scab do not enable the 𝛼-gal nanoparticles to interact with
anti-Gal and to activate the complement cascade; therefore
these nanoparticles may have no beneficial effects in such
wounds.
As mentioned above, 𝛼-gal nanoparticles were found to
display high stability during storage at 4∘C or −20∘C for at
least 4 years, as indicated by conserving their ability to bind
the anti-Gal Ab and activate serum complement even after
such prolonged storage (unpublished observations). This
suggests that 𝛼-gal nanoparticles may be applied to wounds
and burns by a variety of methods and wound care devices.
In addition to direct application of 𝛼-gal nanoparticles as
suspension, these nanoparticles may be stored in a dried
form on wound dressing and then applied to the wound
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as part of the dressing. 𝛼-gal nanoparticles may also be
applied to large areas of wounds and burns in an aerosol form
(i.e., stored as a suspension under pressure in a container
that can spray the suspension in an aerosolized form), or
as foam. These nanoparticles may further be incorporated
into biodegradable scaffold materials such as natural or
recombinant collagen. Dressings that include collagen sheets
are used for treatment of large wounds and burns. Since
collagen enables effective diffusion of complement proteins
and immunoglobulins from the fluid film of the wound, anti-
Gal/𝛼-gal nanoparticles interaction may occur within colla-
gen sheets placed on skin injuries. In addition, nanoparticles
may diffuse from the collagen sheet into the wound. The
ensuing complement activation will generate chemotactic
factors that recruit macrophages into the treated injuries and
accelerate healing in these injuries.
11. Future Directions: 𝛼-gal Nanoparticles
Treatment of Internal Injuries
Healing of internal injuries is mediated by mechanisms
similar to those in skin injuries and involves recruitment
and activation of macrophages as a prerequisite for repair
and regeneration [68–70]. Thus, 𝛼-gal nanoparticles may
also accelerate healing of various internal injuries, thereby
restoring the original structure and function of the injured
tissue and avoiding scar formation. Three of the possible
uses of 𝛼-gal nanoparticles in treatments of internal injuries,
which may be of interest to study, are as follows.
11.1. Healing of Surgical Incisions. Surgical incisions, their
suturing, and the resulting internal injuries represent a major
part of the morbidity of the abdominal surgery. Administra-
tion of 𝛼-gal nanoparticles to such injuries may accelerate
their healing as in skin injuries. In order to ensure retention
of the nanoparticles at the site of their administration 𝛼-gal
nanoparticles should be introduced in semisolid biodegrad-
able “fillers” such as hydrogel or fibrin glue. Diffusion of anti-
Gal and complement within such fillers is likely to result
in interaction with the 𝛼-gal nanoparticles and activation of
the healing process described in Figure 1. Similarly, collagen
sheets or other biodegradable scaffolds containing 𝛼-gal
nanoparticles and applied together with a surgical mesh may
accelerate the healing of the abdominal wall following hernia
surgery.
11.2. Regeneration of Postinfarction Ischemic Myocardium. In
myocardial infarction, cardiomyocytes in the ischemic area
die, resulting in injury of the myocardium. As in wound
healing, macrophages migrate to the injured myocardium,
debride it of dead cells, and secrete cytokines/growth factors
that induce angiogenesis and recruitment of mesenchymal
stem cells or of myocardium progenitor cells from uninjured
areas of the heart (cf. [71, 72]). If the size of the injury is
small, these stem and progenitor cells are instructed by the
ECM to differentiate into cardiomyocytes that repopulate the
tissue and restore its physiologic activity. However, if the
ischemic area is large, the outcome of the healing process
is fibrosis which occurs faster than the regenerative process,
resulting in irreversible scar formation and impairment of
myocardium activity. It is possible to inject 𝛼-gal nanopar-
ticles into the ischemic myocardium by a catheter navigated
into the left ventricle. Such injection will result in rapid and
extensive recruitment of macrophages, as previously shown
in ischemic myocardium of GT-KO mice [23]. Activation
of the recruited macrophages by interaction with anti-Gal
coated 𝛼-gal nanoparticles may induce angiogenesis and
effective recruitment of stem cells which, in turn, will be
instructed by the ECM to differentiate into cardiomyocytes
that repopulate and regenerate the injured tissue. In analogy
with prevention of scar formation in wounds (Figure 5) it
is possible that the regeneration of the injured myocardium
because of the accelerated healing by 𝛼-gal nanoparticlesmay
occur before the onset of fibrosis.
11.3. Regeneration of Injured Nerves. Regeneration of nerves
requires growth of multiple sprouts from the injured axons.
The nerve can regenerate if one of the sprouts “succeeds”
in growing across the lesion and penetrating into the distal
axonal tube. This regrowth of an axon sprout into the distal
axonal tube can occur only within a given period of time
after injury since the process of fibrosis of the nerve lesion
is also initiated shortly after the injury. Thus, if sprouts of
the severed axons fail to “find” the distal axonal tubes and
grow into them, the default fibrosis process will “take over,”
resulting in formation of dense connective tissue in the lesion
area. Such fibrosis will block further growth of sprouts into
distal axonal tubes. The extent of sprout growth in injured
nerves is dependent on the angiogenesis within lesion sites
since the axonal sprouts grow along de novo formed capil-
laries [73]. Formation of capillaries is dependent on VEGF
secretion by macrophages recruited into the nerve lesion site.
This process of axonal regrowth may be amplified by 𝛼-gal
nanoparticles. As illustrated in Figure 1, anti-Gal binding to
𝛼-gal nanoparticles results in complement activation, rapid
chemotactic recruitment of macrophages, and activation of
these macrophages to secrete a variety of cytokines/growth
factors includingVEGF [19]. It is therefore possible that appli-
cation of 𝛼-gal nanoparticles to nerve lesion sites in spinal
cord or in peripheral nerve injuries shortly after the injury
will induce rapid recruitment of macrophages. The recruited
macrophages will be further activated to secret VEGF into
the lesion and induce angiogenesis resulting in formation of
an extensive capillaries network. These multiple capillaries,
in turn, will enable growth of many axonal sprouts, thereby
increasing the probability that some of these sprouts will
“find” the distal axonal tubes and thus, will regenerate the
injured nerve.
12. Conclusions
Wound healing therapy by 𝛼-gal nanoparticles harnesses the
immunological potential of the natural anti-Gal Ab which
is the most abundant Ab in humans. Application of 𝛼-gal
nanoparticles to wounds results in binding of anti-Gal to the
multiple 𝛼-gal epitopes on these nanoparticles. This Ag/Ab
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interaction activates the complement system and generates
complement cleavage chemotactic factors that induce rapid
recruitment of macrophages. The recruited macrophages
interact with the anti-Gal coating 𝛼-gal nanoparticles via
their Fc𝛾R. Such macrophages are activated to secrete
cytokines/growth factors that mediate healing and recruit
stem cells. In GT-KO mice and GT-KO pigs, 𝛼-gal nanopar-
ticles reduce the healing time of wounds and burns by
40–60% and decrease or eliminate scar formation without
formation of keloids. Since the mechanism for repair and
regeneration is the same for external and internal injuries, it is
possible that administration of𝛼-gal nanoparticles to internal
injuries such as wounds associated with surgical incisions,
postinfarction ischemicmyocardium, and nerve injuries may
induce appropriate healing of the injured tissues, instead of
fibrosis and scar formation.
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